https://www.selleckchem.com/pr....oducts/enarodustat.h
3 vs. 59.1%, odds ratio [OR] 0.82, p = 0.004) and shorter LOS (median 6 vs. 7 days, RR 0.88, p less then 0.001), but also predicted higher THCs (+2850.3 US dollars, p = 0.001). CONCLUSIONS In frail patients, the use of RARC did not result in better short-term outcomes except for one-day advantage in LOS. Conversely, in non-frail patients, the use of RARC resulted in lower complication rates and shorter LOS at the cost of higher THCs. In consequence, the benefit of RARC appears relatively marginal in frail patients and our data do no
Beğen
Yorum Yap
Paylaş
